Nelson Dusetti: The importance of molecular signatures in the personalization of treatments for PDAC
Nelson Dusetti shared on LinkedIn:
“We are pleased to announce the release of our article in The Francophone Journal HGOD, Hépato-Gastro and Oncologie Digestive addressing the importance of molecular signatures in the personalization of treatments for pancreatic ductal adenocarcinoma (PDAC).
The severity of this disease, combined with the limited available treatments and the variability in therapeutic responses, highlights the urgent need for treatment personalization. Recent research has identified molecular signatures based on transcriptomic analyses and chemotherapy sensitivity tests. Ongoing clinical trials are currently evaluating their effectiveness in guiding treatments for PDAC patients.
We invite you to read this article and follow our research to learn how these innovations could transform the management of this disease.”
Tissue and blood molecular markers
Authors: Jérôme Cros, Rémy Nicolle, Nelson Dusetti
Moreposts featuring Nelson Dusetti on oncodaily.com
Nelson Dusetti is a Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023